China Biologic Products Holdings Inc represents a strong commitment to providing high-quality biopharmaceutical products in China and abroad. The company focuses on the development, manufacturing, and marketing of plasma-based products for the treatment of various diseases. With a dedication to innovation, China Biologic Products Holdings Inc aims to meet the growing demand for safe and effective therapies. The company prioritizes patient safety and strives to maintain the highest standards of quality and compliance in all aspects of its operations. By consistently delivering reliable and life-saving products, China Biologic Products Holdings Inc has earned a reputation as a trusted and leading global biopharmaceutical company.

China Biologic Products Holdings Inc, a leading biopharmaceutical company, is primarily present in China. With its headquarters in Beijing, the company has a strong presence in various regions across the country. It operates a network of plasma collection centers and manufacturing facilities strategically located in provinces such as Shandong, Hubei, and Guizhou, among others. China Biologic Products Holdings Inc also has a significant presence in international markets. It exports its products to over 20 countries, including the United States, Germany, France, Italy, and Australia, contributing to its global outreach and expansion efforts.

China Biologic Products Holdings Inc. has achieved several significant milestones in its history. One notable milestone includes the company's successful listing on the NASDAQ stock exchange in 2008, further enhancing its global presence and visibility. In 2013, China Biologic received approval from the China Food and Drug Administration (CFDA) for its plasma-based products, enabling it to meet the growing demand in the Chinese market. Additionally, the company has consistently pursued strategic acquisitions and collaborations to expand its product portfolio and market reach. These achievements have positioned China Biologic Products Holdings Inc. as a leading provider of plasma-based biopharmaceutical products in China and beyond.

China Biologic Products Holdings Inc is a leading biopharmaceutical company headquartered in Beijing, China. Established in 2002, the company specializes in the research, development, manufacturing, and marketing of plasma-based products for the treatment of various diseases. With a focus on producing high-quality biologic products, China Biologic Products Holdings Inc has earned a strong reputation in the global healthcare industry. The company's dedication to innovation and advanced technology has propelled its growth over the years, making it a trusted provider of plasma-based therapies. China Biologic Products Holdings Inc continues to expand its product portfolio and geographical presence, striving to improve healthcare outcomes worldwide.

The main competitors of China Biologic Products Holdings Inc in the market include Grifols SA, CSL Limited, and Shire plc.

China Biologic Products Holdings Inc is primarily active in the biopharmaceutical industry.

China Biologic Products Holdings Inc is engaged in the research, development, manufacturing, and sale of plasma-based biopharmaceutical products. The company primarily specializes in the production of human plasma-based products such as albumin, immunoglobulin, and other plasma-derived products for the treatment of various medical conditions. With a strong focus on the Chinese market, China Biologic Products Holdings Inc operates through a vertically integrated business model, encompassing plasma collection, production, testing, and distribution. The company's commitment to quality and adherence to global industry standards has positioned them as a leading provider of biopharmaceutical products in China, meeting the healthcare needs of patients worldwide.

De China Biologic Products Holdings K/W is 17,50.

De China Biologic Products Holdings KUV is 6,16.

De AlleAktien Kwaliteitsscore voor China Biologic Products Holdings is 8/10.

De verwachte China Biologic Products Holdings omzet is 771,10 mln. USD.

De verwachte China Biologic Products Holdings winst is 271,52 mln. USD.

China Biologic Products Holdings Inc is a leading provider of biological products in China, specializing in the manufacturing and sale of plasma products and other biological products. The company is divided into several business segments, each specializing in the production of various types of plasma products and other biological products. One of the key business segments of China Biologic Products Holdings Inc is the manufacturing of human plasma protein. This includes albumin, immunoglobulin, and factor concentrates such as factor VIII and factor IX, which are used in the treatment of blood clotting disorders. The company operates multiple plasma collection centers in China and produces these products in a modern manufacturing facility. Another important business area for the company is the production of animal plasma products. This includes animal antibodies and animal proteins that are used for research and development in the field of biomedical sciences. China Biologic Products Holdings Inc has specialized manufacturing facilities for the production of animal plasma products. In addition to manufacturing and selling plasma products and other biological products, the company is also involved in research and development. The company continuously invests in the development of innovative products and technologies to strengthen its competitive position and expand its product range. Furthermore, China Biologic Products Holdings Inc has a sales platform that allows the company to distribute its products worldwide. The company serves customers in Asia, Europe, North America, and other regions, and has a strong presence in the global biopharmaceutical industry. Overall, the business model of China Biologic Products Holdings Inc is focused on the manufacturing and sale of biological products, particularly plasma products. The various business segments of the company, including the manufacturing of human plasma protein, animal plasma products, and research and development, are designed to expand the product range and strengthen the company's competitive position. The strong presence of China Biologic Products Holdings Inc in the global market and its ability to distribute products worldwide make it an important player in the biopharmaceutical industry. In conclusion, China Biologic Products Holdings Inc follows a business model that aims for continuous expansion and improvement of the product range. Through investment in research and development and continuous improvement of the manufacturing process, the company strives to offer its customers high-quality biological products to improve their health and well-being.

China Biologic Products Holdings keert een dividend van 0 USD uit, verdeeld over betalingen per jaar.

De dividend kan momenteel niet worden berekend voor China Biologic Products Holdings of het bedrijf keert geen dividend uit.

De ISIN van China Biologic Products Holdings is KYG215151047.

Het WKN van China Biologic Products Holdings is A2DU6G.

De ticker van China Biologic Products Holdings is CBPO.

Binnen de laatste 12 maanden betaalde China Biologic Products Holdings een dividend van . Dit komt overeen met een dividendrendement van ongeveer . Voor de komende 12 maanden zal China Biologic Products Holdings naar verwachting een dividend van 0 USD betalen.

De dividendrendement van China Biologic Products Holdings is momenteel .

China Biologic Products Holdings betaalt elk kwartaal een dividend uit. Dit wordt uitgekeerd in de maanden .

China Biologic Products Holdings betaalde de afgelopen 0 jaar elk jaar dividend.

Voor de komende 12 maanden wordt een dividend van 0 USD verwacht. Dit komt overeen met een dividendrendement van 0 %.

China Biologic Products Holdings wordt toegewezen aan de sector 'Gezondheid'.

Om het laatste dividend van China Biologic Products Holdings van 17-9-2024 ter hoogte van 0 USD te ontvangen, moest je het aandeel voor de ex-datum op 17-9-2024 in je portefeuille hebben.

De laatste dividenduitkering vond plaats op 17-9-2024.

In het jaar 2023 heeft China Biologic Products Holdings 0 USD aan dividenden uitgekeerd.

De dividenden van China Biologic Products Holdings worden in USD uitgekeerd.